EDWARDS ANNOUNCES KEY EVENTS FOR EUROPCR 2022

Rhea-AI Summary

Edwards Lifesciences (NYSE: EW) has announced key events at EuroPCR 2022, occurring from May 17 to 20 in Paris. Notable presentations include:

Results from the PARTNER 2 and 3 trials

on May 17, focusing on aortic valve replacement and its effects on cardiac health.

One-year results of the PASCAL system

for tricuspid valve repair on May 19, showing significant TR reduction. Additionally,

30-day outcomes from the TriCLASP study

will be presented on May 19, marking its first data release.

Positive

• Presenting significant clinical trial results at EuroPCR 2022 which may enhance the visibility and credibility of Edwards' cardiovascular solutions.
• The PASCAL system demonstrates notable effectiveness in reducing tricuspid regurgitation, which could drive further adoption and sales.

Negative

• None.

PARIS, May 16, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) announced key events for the company during EuroPCR 2022, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). The event takes place May 17 to 20 at the Palais des Congrès in Paris.

Among the scheduled data presentations are a EuroPCR 2022 abstract submission and three late-breaking clinical trials:

• Staging aortic stenosis based on cardiac damage: evolution and two-year outcomes – On May 17, results from a pooled analysis of patients treated in the PARTNER 2 and 3 trials undergoing either transcatheter or surgical aortic valve replacement (AVR) will be discussed, focusing on the impact of AVR on progression or regression of extra-valvular cardiac damage and its association with subsequent prognosis.
  
  
• Transcatheter tricuspid valve repair: CLASP TR study one-year results – On May 19, one-year results of the Edwards PASCAL transcatheter valve repair system will be discussed. One-year results were previously presented on April 4, 2022, at the 71st Annual Scientific Session and Expo (ACC.22) in Washington, D.C., and patient outcomes from the trial demonstrated significant tricuspid regurgitation (TR) reduction. The Edwards PASCAL transcatheter valve repair system is approved for use in Europe.
  
  
• TriCLASP post-market study: 30-day outcomes – On May 19, 30-day outcomes of the Edwards PASCAL transcatheter valve repair system will be presented. This will be the first data presentation from the TriCLASP post-market study, which is following outcomes of patients at centers throughout Europe whose tricuspid valve disease was treated with the Edwards PASCAL system.
  
  
• Cardioband TR early feasibility study: one-year results – On May 19, one-year results of the Edwards Cardioband tricuspid valve reconstruction system will be discussed. Six-month results were presented in June 2021 at TVT: The Structural Heart Summit in Chicago, showing favorable 30-day outcomes sustained at six months.

About Edwards Lifesciences
Edwards Lifesciences is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. We are driven by a passion for patients, dedicated to improving and enhancing lives through partnerships with clinicians and stakeholders across the global healthcare landscape. For more information, visit Edwards.com and follow us on Facebook, Instagram, LinkedIn, Twitter and YouTube.

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict. Our forward-looking statements speak only as of the date on which they are made, and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement. Investors are cautioned not to unduly rely on such forward-looking statements.

Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those expressed or implied by the forward-looking statements based on a number of factors as detailed in the company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2021, and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2022. These filings, along with important safety information about our products, may be found at Edwards.com.

The Edwards Cardioband System, and the Edwards PASCAL Systems are for professional use where CE marking is accepted. For a listing of indications, contraindications, warnings, precautions and adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable). Edwards devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity.

In the United States INVESTIGATIONAL DEVICES. CAUTION: Limited to investigational use in the United States. These devices are limited to investigational use and not available for marketing or commercial sale in the United States.

Edwards, Edwards Lifesciences, the stylized E logo, Cardioband, CLASP, PARTNER, PASCAL and TriCLASP are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/edwards-announces-key-events-for-europcr-2022-301547659.html

SOURCE Edwards Lifesciences Corporation

FAQ

What key events is Edwards Lifesciences showcasing at EuroPCR 2022?

Edwards Lifesciences is presenting several significant clinical trial results, including findings from the PARTNER 2 and 3 trials, one-year outcomes of the PASCAL system, and 30-day outcomes from the TriCLASP study.

When will Edwards Lifesciences present the results from the PARTNER trials at EuroPCR 2022?

The results from the PARTNER 2 and 3 trials will be discussed on May 17, 2022.

What are the results being presented for the PASCAL system at EuroPCR 2022?

The one-year results of the Edwards PASCAL transcatheter valve repair system will be discussed on May 19, 2022, showcasing a significant reduction in tricuspid regurgitation.

When will the first data from the TriCLASP post-market study be released?

The 30-day outcomes of the TriCLASP study will be presented on May 19, 2022.

What advancements is Edwards Lifesciences making in the tricuspid valve treatment area?

Edwards is showcasing the effectiveness of its PASCAL transcatheter valve repair system, which has shown significant improvement in patient outcomes.